Analyzing Climb Bio (NASDAQ:CLYM) & Lunai Bioworks (NASDAQ:RENB)

Lunai Bioworks (NASDAQ:RENB) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Risk and Volatility

Lunai Bioworks has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500.

Profitability

This table compares Lunai Bioworks and Climb Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-60.38%	-47.04%
Climb Bio	N/A	-23.10%	-22.47%

Valuation & Earnings

This table compares Lunai Bioworks and Climb Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$88.43 million	($0.77)	-0.17
Climb Bio	N/A	N/A	-$73.90 million	($0.70)	-3.04

Climb Bio is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 0.8% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Lunai Bioworks and Climb Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	0	0	0	0	0.00
Climb Bio	0	0	4	2	3.33

Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 322.54%. Given Climb Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Lunai Bioworks.

Summary

Climb Bio beats Lunai Bioworks on 9 of the 12 factors compared between the two stocks.

About Lunai Bioworks

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.